February 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Maxime Dely: What If One Technology Could Transform Patients’ Lives?

Maxime Dely/LinkedIn

Dec 18, 2025, 23:56

Maxime Dely: What If One Technology Could Transform Patients’ Lives?

Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:

“Sickle cell disease: What if one technology could transform patients’ lives?

Sickle cell disease is the most common genetic disorder in France, affecting 25,000 to 30,000 people. It remains a complex condition marked by severe pain, microvascular occlusions, strokes, necrosis, jaundice, and episodes of acute hemolytic anemia — all profoundly impacting daily life.

Despite ongoing prevention efforts, the disease continues to progress.
Yet one interventional treatment is truly reshaping patient care: automated red blood cell exchange.

Still underrecognized, this procedure — performed through apheresis systems — brings major benefits supported by numerous studies:

* Drastic reduction in acute crises by removing sickled red cells responsible for vascular occlusion.
* Significantly less iron overload compared with standard transfusion — a crucial long-term advantage.
* Faster procedure, enabling 2 to 3 times more red cell units to be exchanged in the same amount of time.
* More spaced-out sessions, greatly improving comfort and quality of life for patients.

Red blood cell exchange is not just an alternative — it is a major therapeutic advancement for a disease that remains insufficiently visible.

Promoting access to this therapy means offering patients safer, more effective, and more humane care.”

Maxime Dely: What If One Technology Could Transform Patients' Lives?